Financials data is unavailable for this security.
View more
Year on year Abionyx Pharma SA had revenues fall -11.65% from 5.25m to 4.64m, though the company grew net income from a loss of 4.21m to a smaller loss of 3.52m.
| Gross margin | 13.32% |
|---|---|
| Net profit margin | -75.82% |
| Operating margin | -73.53% |
| Return on assets | -22.95% |
|---|---|
| Return on equity | -46.62% |
| Return on investment | -32.52% |
More ▼
Cash flow in EURView more
In 2023, Abionyx Pharma SA did not generate a significant amount of cash. Cash Flow from Financing totalled 3.89m or 83.75% of revenues. In addition the company used 3.70m for operations while cash used for investing totalled 130.00k.
| Cash flow per share | -0.1147 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.246 |
|---|---|
| Tangible book value per share | 0.0765 |
More ▼
Balance sheet in EURView more
| Current ratio | 1.75 |
|---|---|
| Quick ratio | 1.70 |
| Total debt/total equity | 0.4279 |
|---|---|
| Total debt/total capital | 0.2997 |
More ▼
Growth rates in EUR
Growth rate information is not available.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 19.54 |
